

Oxidative Cyclization Approach to Benzimidazole Libraries

*Eric P. Arnold, Prolay K. Mondal, and Daniel C. Schmitt**

Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States

Supporting Information

Table of Contents

General Information	S2
General Procedures	S3
Spectroscopic Data for Scheme 2	S4
Spectroscopic Data for Scheme 3	S29
Experimental Procedures for Scheme 4	S39
Experimental Procedures for Scheme 5	S41

General Information: All reagents were obtained from commercial suppliers and used without further purification, unless otherwise noted. All solvents used were purchased anhydrous and transferred by nitrogen-purged syringe. Silica gel chromatography was performed using medium pressure Biotage or ISCO systems employing columns pre-packaged by various commercial vendors including Biotage and ISCO. ^1H and ^{13}C NMR characterization data were collected at 300 K on a Bruker AS-400 spectrometer operating at 400 and 100 MHz (respectively) with chemical shifts reported in parts per million relative to CD_3OD (^1H NMR: 3.31 ppm; ^{13}C NMR: 49.0 ppm). LC-MS were acquired using a Waters Acquity UPLC equipped with a Waters Acquity HSS T3 column, water/MeCN gradient and 0.1% v/v formic acid as modifier.

General Library Procedure A: To a plate of 2-dram vials with septum caps containing the anilines (0.40 mmol, 1.0 equiv) was added THF (2.5 mL, 0.16 M) followed by LiHMDS (0.40 mL, 1 M solution in THF, 1.0 equiv). The resulting solutions were stirred at 23 °C for 20 minutes. Benzonitrile (41 µL, 0.40 mmol, 1.0 equiv) was added via syringe and the reactions were stirred at 23 °C for 17 h. Solvent was then removed via genevac to provide the crude amidine intermediates. DMSO (2.5 mL, 0.16 M) and Cu(OAc)₂ (145 mg, 0.80 mmol, 2.0 equiv) were added followed by glacial acetic acid (0.46 mL, 8 mmol, 20 equiv). Without capping the vials, they were placed in a preheated 110 °C plate and stirred for 17 h open to the atmosphere. The vials were cooled and poured into Na₂CO₃ (20 mL, saturated aqueous solution). The mixtures were extracted with EtOAc (2 X 5 mL) and filtered through Na₂SO₄ plugs. Solvent was removed via genevac. The resulting crude benzimidazoles were dissolved in 1 mL DMSO and submitted for high-throughput purification (column: Waters Sunfire C18 19x100, 5µ; Mobile phase A: 0.05% TFA in water (v/v); Mobile phase B: 0.05% TFA in acetonitrile (v/v)).

General Library Procedure B:

Imidoyl triflate stock solution: To a dry flask under N₂ atmosphere was added N-methyl benzamide (1.0 equiv per reaction) followed by CH₂Cl₂ (0.4 M) and 2,6-lutidine (2.2 equiv). The flask was cooled to 0 °C and triflic anhydride (1.1 equiv per reaction) was added dropwise. The solution was allowed to warm to 23 °C over 2.5 h.

Amidine formation / oxidative cyclization: To a plate of 2-dram vials with septum caps containing the anilines (1.2 equiv) was added CH₂Cl₂ (0.8 M) followed by the imidoyl triflate solution (1.0 equiv per vial). Vials were stirred at 23 °C for 15 h. Reaction mixtures were concentrated under a stream of N₂, then partitioned between water and EtOAc (1:1). The organic phases were separated and the aqueous phases were re-extracted with EtOAc. The combined organic phases were filtered through Na₂SO₄ plugs into 2 dram vials and concentrated under a stream of N₂. To the resulting crude amidines was added MeCN (0.25 M) and PhI(OAc)₂ (2.0 equiv per vial). The vials were sealed with pressure-release caps and heated to 100 °C for 2 h. The vials were cooled and concentrated under a stream of N₂. The resulting residues were diluted with H₂O, extracted with EtOAc (2x), and filtered through Na₂SO₄ plugs. Solvent was removed under a stream of N₂. The resulting crude benzimidazoles were dissolved in 1 mL DMSO and submitted for high-throughput purification (column: Waters Sunfire C18 19x100, 5µ; Mobile phase A: 0.05% TFA in water (v/v); Mobile phase B: 0.05% TFA in acetonitrile (v/v)).

Spectroscopic Data for Scheme 2


Compounds were prepared in parallel format via General Library Procedure A.

Compound **2f** and **2i** has been fully characterized previously and NMR spectra were matched to reported values:

2f) Huang, J.; He, Y.; Wang, Y.; Zhu, Q. *Chem. Eur. J.* **2012**, *18*, 13964-13967.

2i) Kim, J.; Kim J.; Lee, H.; Lee, B. M.; Kim, B. H. *Tetrahedron* **2011**, *67*, 8027-8033.



4-methoxy-2-phenyl-1H-benzo[d]imidazole (**2a**)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.15 (d, *J*=7.3 Hz, 2H), 7.69 - 7.80 (m, 3H), 7.54 (t, *J*=8.2 Hz, 1H), 7.37 (d, *J*=7.8 Hz, 1H), 7.13 (d, *J*=7.8 Hz, 1H), 4.11 (s, 3H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ 149.26, 147.72, 133.43, 133.17, 129.59, 129.55, 127.72, 127.37, 123.16, 106.27, 105.41, 55.36 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₂N₂O (M+H): 225.1, Found: 225.3





4-fluoro-2-phenyl-1H-benzo[d]imidazole (2b)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.12 - 8.22 (m, 2H), 7.66 - 7.78 (m, 3H), 7.59 (d, *J*=7.9 Hz, 1H), 7.50 (br d, *J*=4.7 Hz, 1H), 7.30 (t, *J*=9.2 Hz, 1H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ 151.70, 149.21, 136.36, 132.60, 129.43, 127.53, 125.79, 124.13, 110.18, 110.01, 109.47 ppm.

LC-MS (ESI) Calcd. for C₁₃H₉FN₂ (M+H): 213.1, Found: 213.2





5,7-dimethyl-2-phenyl-1H-benzo[d]imidazole (2e)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.14 - 8.20 (m, 2H), 7.70 - 7.81 (m, 3H), 7.42 (s, 1H), 7.25 (s, 1H), 2.68 (s, 3H), 2.53 (s, 3H) ppm.

¹³C NMR (126 MHz, METHANOL-*d*₄) δ 149.25, 136.82, 132.86, 132.62, 130.26, 129.50, 128.16, 127.55, 124.24, 123.67, 110.48, 20.24, 15.44 ppm.

LC-MS (ESI) Calcd. for C₁₅H₁₄N₂ (M+H): 223.1, Found: 223.2



5-(methylsulfonyl)-2-phenyl-1H-benzo[d]imidazole (2g)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.27 (d, *J* = 1.6 Hz, 1H), 8.16-8.14 (m, 2H), 7.94 (dd, *J* = 1.6 Hz, 8.6 Hz, 1H), 7.87 (d, *J* = 8.4 Hz, 1H), 7.65-7.63 (m, 3H), 3.19 (s, 3H) ppm.


¹³C NMR (101 MHz, METHANOL-*d*₄) δ 152.6, 150.5, 141.9, 137.4, 133.2, 130.7, 129.0, 128.6, 123.8, 116.6, 116.4, 45.1 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₂N₂O₂S (M+H): 273.1, Found: 273.3.


00110442-3005-004.001.esp
 1H
 METHANOL-d4
 11 H's




400 MHz
 CD₃OD




00110442-3005-004-REDO.002.esp
 13C
 METHANOL-d4
 9 C's



100 MHz
 CD₃OD



1-(2-phenyl-1H-benzo[d]imidazol-7-yl)pyridin-2(1H)-one (2h)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.06 - 8.17 (m, 2H), 7.87 (d, *J*=8.20 Hz, 1H), 7.60 - 7.77 (m, 5H), 7.47 (d, *J*=7.02 Hz, 1H), 6.75 (d, *J*=9.28 Hz, 1H), 6.61 - 6.59 (m, 1H) ppm.



¹³C NMR (101 MHz, METHANOL-*d*₄) δ 164.7, 153.5, 143.3, 140.3, 137.1, 134.0, 132.7, 130.9, 129.6, 129.2, 126.9, 126.7, 124.5, 122.1, 116.2, 109.2 ppm.

LC-MS (ESI) Calcd. for C₁₈H₁₄N₃O (M+H): 288.3, Found: 288.4


00110442-3005-022.3.fid
 NMR System BNMR_311-1 400 BH013110
 Pfizer Confidential
 proton DMSO {C:\Bruker\TopSpin3.0} arnoldep 21



¹H NMR (400 MHz, DMSO-*d*₆) δ 7.33 – 7.19 (m, 2H), 6.97 (dd, *J* = 8.2, 0.9 Hz, 1H), 6.94 – 6.85 (m, 2H), 6.76 (dd, *J* = 5.0, 1.9 Hz, 3H), 6.68 (t, *J* = 7.9 Hz, 1H), 6.51 (dd, *J* = 7.7, 0.9 Hz, 1H), 5.93 (dd, *J* = 9.9, 1.3 Hz, 1H), 5.75 (td, *J* = 6.7, 1.3 Hz, 1H).





6-methoxy-2-phenyl-1H-benzo[d]imidazole (2j)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.95 - 8.00 (m, 2H), 7.54 - 7.66 (m, 4H), 7.13 (d, *J*=2.3 Hz, 1H), 7.10 (s, 1H), 3.80 (s, 3H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ 159.36, 148.61, 133.24, 132.79, 129.72, 127.24, 125.88, 122.78, 116.54, 114.30, 95.60, 55.14 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₂N₂O (M+H): 224.09, Found: 224.3





6-methyl-2-phenyl-1H-benzo[d]imidazole (2k)




¹H NMR (400 MHz, METHANOL-*d*₄): δ 8.04 – 7.98 (m, 2H), 7.68 – 7.56 (m, 4H), 7.50 (s, 1H), 7.34 (dd, *J*=8.6, 0.8 Hz, 1H), 2.45 (s, 3H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ 149.19, 137.26, 133.32, 132.24, 130.07, 129.72, 127.89, 127.42, 123.05, 113.16, 113.05, 20.29 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₂N₂ (M+H): 209.1, Found: 209.2



tert-butyl methyl((2-phenyl-1H-benzo[d]imidazol-6-yl)methyl)carbamate (2l)





¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.13 (br d, *J*=7.41 Hz, 2 H), 7.70 - 7.90 (m, 4 H), 7.68 (br s, 1 H), 7.52 (d, *J*=8.20 Hz, 1 H), 4.64 (s, 2 H), 2.91 (s, 3 H), 1.50 (s, 9 H) ppm.


¹³C NMR (101 MHz, METHANOL-*d*₄) δ 159.3, 158.1, 137.3, 133.8, 132.4, 131.0, 130.5, 128.6, 128.2, 126.1, 115.7, 114.1, 81.6, 54.2, 34.7, 28.9 ppm.

LC-MS (ESI) Calcd. for C₂₀H₂₄N₃O₂ (M+H): 338.4, Found: 338.4

00110442-3005-022.001.esp
 1H
 METHANOL-d4
 31 H's





2-phenyl-6-(pyridin-2-yl)-1H-benzo[d]imidazole (2m)




¹H NMR (400 MHz, METHANOL-*d*₄) δ ppm 8.76 (d, *J*=4.7 Hz, 1 H) 8.40 (d, *J*=1.2 Hz, 1 H) 8.12 - 8.22 (m, 5 H) 7.93 (d, *J*=8.6 Hz, 1 H) 7.71 - 7.80 (m, 3 H) 7.60 (br t, *J*=1.8 Hz, 1 H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ ppm 155.53, 151.96, 147.48, 139.83, 135.00, 134.85, 132.82, 129.56, 127.40, 124.72, 124.64, 123.32, 122.47, 114.31, 112.94, 111.38 ppm.

LC-MS (ESI) Calcd. for C₁₈H₁₃N₃ (M+H): 272.1, Found: 272.1




1-benzyl-6-phenyl-1,7-dihydroimidazo[4,5-f]indazole (2n)





¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.38 (s, 1H), 8.11 (m, 2H), 7.65 - 7.75 (m, 5H), 7.21 - 7.31 (m, 5H), 5.73 (s, 2H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ 149.2, 140.5, 138.3, 134.2, 131.4, 131.3, 130.1, 129.3, 129.2, 128.7, 128.6, 127.1, 125.8, 114.5, 112.5, 110.9, 54.5 ppm.


LC-MS (ESI) Calcd. for C₂₁H₁₇N₄ (M+H): 325.4, Found: 325.4




¹H



¹³C





7-phenyl-6H-imidazo[4',5':3,4]benzo[1,2-d]thiazole (2o)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 9.29 (s, 1 H), 8.10 - 8.20 (m, 3 H), 7.84 (d, *J*=8.98 Hz, 1 H), 7.62 - 7.70 (m, 3 H) ppm.

¹³C NMR ¹³C NMR (101 MHz, METHANOL-*d*₄) δ 155.5, 153.1, 152.8, 133.5, 133.2, 133.0, 130.8, 128.5, 128.0, 122.1, 121.1, 113.4 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₀N₃S (M+H): 252.3, Found: 252.3



1-(2-phenyl-6,7-dihydroimidazo[4,5-g]indol-8(1H)-yl)ethan-1-one (2p)





¹H NMR (400 MHz, METHANOL-*d*₄) δ 8.12 (s, 1H) 8.10 (d, *J*=1.56 Hz, 1H) 7.71 - 7.82 (m, 3H) 7.49 - 7.52 (m, 1H) 7.47 (s, 1H) 4.36 (t, *J*=8.78 Hz, 2H) 3.45 (t, *J*=8.59 Hz, 2H) 2.40 (s, 3H) ppm.


¹³C NMR (101 MHz, METHANOL-*d*₄) δ 170.2, 147.7, 134.1, 133.3, 129.8, 129.7, 128.0, 127.4, 123.0, 120.6, 109.8, 100.0, 49.8, 28.3, 22.0 ppm.

LC-MS (ESI) Calcd. for C₁₇H₁₅N₃O (M+H): 278.1, Found: 278.5

Regioselectivity >20:1 - Assigned by COSY




cosy DMSO {C:\Bruker\TopSpin3.0} schmid24 34



Spectroscopic Data for Scheme 3

Compounds were prepared in parallel format via General Library Procedure B.



5-fluoro-1-methyl-2-phenyl-1H-benzo[d]imidazole (4a)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.81 - 7.95 (m, 2 H) 7.59 - 7.76 (m, 4 H) 7.51 (td, *J*=8.20, 4.68 Hz, 1 H) 7.28 (t, *J*=9.26 Hz, 1 H) 4.01 (s, 3 H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) (C-F coupling observed) δ 154.7, 154.3, 151.8, 139.4, 139.3, 133.6, 131.4, 130.8, 127.2, 127.1, 127.1, 111.8, 111.6, 109.5, 109.4, 33.5 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₂FN₂ (M+H): 227.3, Found: 227.3





4-methoxy-1-methyl-2-phenyl-1H-benzo[d]imidazole (4b)




¹H NMR (500 MHz, METHANOL-*d*₄) δ 7.86 - 7.95 (m, 2 H), 7.70 - 7.85 (m, 3 H), 7.63 (t, *J*=8.19 Hz, 1 H), 7.49 (d, *J*=8.07 Hz, 1 H), 7.21 (d, *J*=8.07 Hz, 1 H), 4.10 (s, 3 H), 4.06 (s, 3 H) ppm.

¹³C NMR (126 MHz, METHANOL-*d*₄) δ 151.6, 149.4, 136.5, 134.6, 131.5, 131.1, 129.2, 124.1, 123.1, 108.6, 106.1, 57.2, 33.6 ppm.

LC-MS (ESI) Calcd. for C₁₅H₁₅N₂O (M+H): 239.3, Found: 239.4





1,5,7-trimethyl-2-phenyl-1H-benzo[d]imidazole (4c)




¹H NMR (400 MHz, METHANOL-*d*₄) δ 7.72 - 7.91 (m, 5 H), 7.45 (s, 1 H), 7.31 (s, 1 H), 4.22 (s, 3 H), 2.91 (s, 3 H), 2.57 (s, 3 H) ppm.

¹³C NMR (101 MHz, METHANOL-*d*₄) δ 151.7, 139.3, 134.4, 133.0, 131.8, 131.4, 131.9, 131.0, 126.4, 124.1, 112.5, 36.2, 21.5, 18.8 ppm.

LC-MS (ESI) Calcd. for C₁₆H₁₇N₂ (M+H): 237.1, Found: 237.4



7-fluoro-1-methyl-2-phenyl-1H-benzo[d]imidazole (4d)





¹H NMR (500 MHz, METHANOL-*d*₄) δ 7.89 (d, *J*=7.18 Hz, 2 H) 7.71 - 7.81 (m, 3 H) 7.59 - 7.65 (m, 1 H) 7.51 - 7.59 (m, 1 H) 7.37 (ddd, *J*=11.74, 8.07, 0.73 Hz, 1 H) 4.18 (d, *J*=1.47 Hz, 3 H) ppm.


¹³C NMR (126 MHz, METHANOL-*d*₄) (C-F coupling observed) δ 154.0, 152.4, 150.4, 137.8, 134.1, 131.3, 130.8, 128.0, 127.9, 125.1, 124.2, 124.1, 112.9, 112.8, 35.6 (2 peaks) ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₁FN₂ (M+H): 227.3, Found: 227.3

Regioselectivity Assigned by ¹³C NMR (N1-CH₃ couples to F)





6-methoxy-1-methyl-2-phenyl-1H-benzo[d]imidazole (4e)



¹H NMR (500 MHz, METHANOL-*d*₄) δ 7.93 (d, *J*=6.83 Hz, 2 H), 7.75 - 7.98 (m, 4 H), 7.41 (d, *J*=2.45 Hz, 1 H), 7.36 (m, 1 H), 4.1 (s, 3 H), 3.98 (s, 3 H) ppm.


¹³C NMR (126 MHz, METHANOL-*d*₄) δ 161.0 151.2, 136.2, 134.4, 131.1, 131.0, 124.2, 118.6, 116.0, 96.5, 56.9, 33.3 ppm.

LC-MS (ESI) Calcd. for C₁₅H₁₅N₂O (M+H): 239.3, Found: 239.3



Preparative scale sequences (Scheme 4) – experimental procedures


Preparative scale synthesis of compound **2e**



Amidine formation – To 3,5-dimethylaniline (340 mg, 2.81 mmol, 1.0 equiv) in a 3-neck round bottom flask fitted with an addition funnel was added THF (17 mL). The flask was cooled to 0 °C in an ice bath and LiHMDS (1 M in THF, 2.81 mL, 2.81 mmol, 1.0 equiv) was added dropwise via addition funnel. The reaction was stirred for 20 min at 0 °C, then benzonitrile (286 mg, 2.81 mmol, 1.0 equiv) was added. The reaction was warmed to 23 °C and stirred for 17 h. Water (30 mL) was added and the mixture was extracted 2X with EtOAc. The combined organic phases were dried over Na₂SO₄, filtered, and concentrated to provide crude amidine intermediate (492 mg, 2.20 mmol, 78% yield) that was used in the subsequent step without purification.

Oxidative cyclization - To the 2-dram vial containing amidine intermediate (2.20 mmol) under air atmosphere was added Cs₂CO₃ (792 mg, 2.43 mmol, 1.1 equiv) and 2,2,2-trifluoroethanol (2.0 mL). Cooled to 0 °C and added PIDA (783 mg, 2.43 mmol, 1.1 equiv). After stirring for 1.5 h, solvent was removed *in vacuo*. The crude mixture was diluted with EtOAc and water; the organic phase was separated, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The residue was chromatographed (20% EtOAc/heptanes to 50% EtOAc/heptanes) to provide **2e** (350 mg, 1.58 mmol, 71% yield).

Preparative scale synthesis of compound **4e**:



Amidine formation - N-methylbenzamide (1.01 g, 7.5 mmol, 1.0 equiv) was dissolved in 20 mL dry dichloromethane in a 125 mL round-bottom flask. 2,6-lutidine (1.9 mL, 16.5 mmol, 2.2 equiv) was then added drop-wise at 23 °C, under nitrogen. Reaction flask was then cooled in an ice-water bath, and trifluoromethanesulfonic anhydride (1.76 mL, 8.3 mmol, 1.1 equiv) was added drop-wise. The dark-pink/wine color solution generated was stirred under nitrogen, and gradually warmed to 23 °C over 2.5 h. A solution of 4-methoxyaniline (1.1 g, 9.0 mmol, 1.2 eq.) in 5 mL dry dichloromethane was then added to the reaction flask, and contents were stirred overnight at 23 °C. Reaction was quenched by adding 10 mL of water. Organic layer was separated, and aqueous layer was extracted with 2x15 mL of ethyl acetate. Combined organic layers were then dried over sodium sulfate, concentrated and purified using silica gel ISCO Combiflash chromatography (0 to 100% ethyl acetate in heptane). Partially pure amidine (1.8 g, 100%) was obtained, which was used as is in the subsequent step.

Oxidative cyclization – amidine intermediate was dissolved in dry acetonitrile (38 mL, c=0.20 M), and transferred to a sealable tube. Diacetoxyiodobenzene (4.80 g, 14.9 mmol, 2.0 equiv) was added in one

portion. The reaction vessel was sealed and heated at 100 °C for 2 h. After cooling to 23 °C, the mixture was diluted with 40 mL EtOAc and washed with 40 mL water. The aqueous layer was extracted with 2 x 30 mL ethyl acetate. Combined organics were dried, concentrated and purified using ISCO (0 to 100% ethyl acetate in heptane) to give 6-methoxy-1-methyl-2-phenyl-1H-benzo[d]imidazole (907 mg, 51% yield over 2 steps).

Spectroscopic Data for Scheme 5

Compounds were prepared in parallel format via General Library Procedure A.


Compounds **6a**, **6b**, and **6c** have been fully characterized previously and NMR spectra were matched to reported values:

6a) Dubey, P. K.; Chowdary, K. S.; Ramesh, B.; Prasada Reddy, P. V. V. *Synth. Commun.* **2010**, *40*, 697-708.

6b) Mishra, A.; Sahu, S.; Dash, N.; Behera, S. K.; Krishnamoorthy, G. *J. Phys Chem. B.* **2013**, *117*, 9469-9477.

6c) Kulkarni, S. S.; Newman, A. H. *Bioorganic & Medicinal Chemistry Letters* **2007**, *17*, 2987-2991.

6-(cyclopropylmethoxy)-2-phenyl-3H-imidazo[4,5-c]pyridine (**6d**)





¹H NMR (400 MHz, CD₃OD): δ 8.58 (s, 1H), 8.15-8.10 (m, 2H), 7.62-7.57 (m, 3H), 7.14 (s, 1H), 4.19 (d, *J* = 7.0 Hz, 2H), 1.38-1.33 (m, 1H), 0.70-0.66 (m, 2H), 0.46-0.42 (m, 2H) ppm.

¹³C NMR (100 MHz, CD₃OD): δ 160.6, 157.9, 148.3, 136.3, 134.3, 132.9, 130.5, 128.5, 92.8, 74.5, 11.1, 3.8 ppm.


LC-MS (ESI) Calcd. for C₁₆H₁₅N₃O (M+H): 266.1, Found: 266.3.

Regioselectivity 2:1 - Assigned by ¹HNMR.



6-methyl-2-phenyl-3H-imidazo[4,5-c]pyridine (6f)

(from 2-methylpyridin-4-amine)





¹H NMR (400 MHz, CD₃OD): δ 8.73 (s, 1H), 8.13-8.10 (m, 2H), 7.56-7.55 (m, 3H), 7.44 (s, 1H), 2.63 (s, 3H) ppm.

¹³C NMR (100 MHz, CD₃OD): (tautomeric mix) δ 157.4, 151.2, 140.7, 133.2, 132.4 (2 peaks), 130.6, 130.5, 130.4, 129.8, 129.7, 128.5, 23.6 ppm.



LC-MS (ESI) Calcd. for C₁₃H₁₁N₃ (M+H): 210.1, Found: 210.1.

Regioselectivity >20:1 - Assigned by ¹HNMR.


00110442-2987-016C.001.esp
 1H
 METHANOL-d4
 10 H's



00110442-2987-016C.002.esp
 13C
 METHANOL-d4
 12 C's



7-fluoro-2-phenyl-1H-imidazo[4,5-c]pyridine (6g)





¹H NMR (400 MHz, CD₃OD): δ 9.04 (s, 1H), 8.58 (d, *J* = 3.9 Hz, 1H), 8.29-8.26 (m, 2H), 7.68-7.63 (m, 3H) ppm.

¹³C NMR (100 MHz, CD₃OD): δ 162.8, 159.4, 149.6, 133.3, 133.2, 130.6, 129.5, 129.0, 127.2, 127.0 ppm.



LC-MS (ESI) Calcd. for C₁₂H₈FN₃ (M+H): 214.1, Found: 214.3.

Regioselectivity 4:1 - Assigned by ¹HNMR.


00110442-2987-002A.001.esp
1H
METHANOL-d4
7 H's



00707660-1276-EA2987-2A.001.esp
13C
METHANOL-d4
8 C's




8-phenyl-9H-purine (6h)




¹H NMR (400 MHz, CD₃OD): δ 9.15 (br s, 1H), 9.03 (s, 1H), 8.25-8.22 (m, 2H), 7.66-7.60 (m, 3H) ppm.


¹³C NMR (100 MHz, CD₃OD): δ 158.2, 157.4, 150.0, 141.1, 132.1, 129.1, 128.0, 127.6, 127.5 ppm.

LC-MS (ESI) Calcd. for C₁₁H₈N₄ (M+H): 197.1, Found: 197.3.





2-isopropyl-8-phenyl-9H-purine (6i)



¹H NMR (400 MHz, CD₃OD): δ 9.15 (s, 1H), 8.24-8.22 (m, 2H), 7.66-7.61 (m, 3H), 3.46--3.40 (m, 1H), 1.47 (d, *J* = 5.9 Hz, 6H) ppm.

¹³C NMR (100 MHz, CD₃OD): 167.4, 162.5, 161.4, 160.4, 139.8, 133.9, 131.7, 130.7, 129.2, 36.8, 21.9 ppm.

LC-MS (ESI) Calcd. for C₁₄H₁₄N₄ (M+H): 239.1, Found: 239.2.

